EsoBiotec’s Post

How can we improve access to advanced therapies? @Dr. Miguel Forte, President-elect of ISCT, International Society for Cell & Gene Therapy recently shared some thoughts about this topic. Our May #BridgingtheGap webinar also included news from the Emily Whitehead Foundation and well as insights into innovative tech and global strategies for improving patient access to care. Read the highlights here: 👉 https://hubs.ly/Q02H1dyt0 #CGT #CancerResearch #Oncology #LifeSciences

Did you already read the interview with Inge Jedema and Jurgen Kuball❓ “Success will be putting the Netherlands firmly on the international map as a leader in cell and gene therapy.” Read the full double-interview with Jurgen Kuball, chair of the Cell and Gene Therapy Workstream management team and head of the Department of Hematology at UMC Utrecht, and Inge Jedema, co-chair and head of Translational Cellular Therapy at The Netherlands Cancer Institute. ➡ https://lnkd.in/dSyxyQ5U #preclinical #drugdevelopment #healthdata #patientengagement #ai #patientcohorts #organoids #cellgenetherapy #smallmolecules #biologics #therapeuticvaccines #regulatoryinnovation #nationaalgroeifonds #NGF #oncology #cancerresearch #cancertherapy

𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲: 𝗔𝘀𝘁𝗲𝗹𝗹𝗮𝘀 𝗮𝗻𝗱 𝗞𝗲𝗹𝗼𝗻𝗶𝗮 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀' 𝗕𝗼𝗹𝗱 𝗟𝗲𝗮𝗽 𝗶𝗻𝘁𝗼 𝗜𝗻 𝗩𝗶𝘃𝗼 𝗖𝗔𝗥-𝗧 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 The landscape of cell and gene therapy is witnessing a remarkable evolution, underscored by Astellas Pharma's recent strategic collaboration with Kelonia Therapeutics This partnership aims to pioneer the development of convertible in vivo CAR-T cell therapies, a ground-breaking approach that could redefine cancer treatment paradigms. Astellas' venture into in vivo CAR-T therapies, facilitated through this collaboration, highlights the industry's shift towards more sophisticated and patient-centric treatment modalities. Kelonia's proprietary technology, designed to activate CAR-T cells within the body, presents a novel pathway to potentially overcome the limitations of current ex vivo methods, offering a glimpse into a future where cancer treatments are not only more effective but also more accessible. This initiative is not just a testament to the power of collaboration in driving innovation but also a reflection of the continuous need for cutting-edge research and development in the cell and gene therapy domain. As professionals in the field, it's imperative that we closely monitor these developments, engage in meaningful discussions, and contribute to the evolution of therapies that promise to transform patient care. #CellAndGeneTherapy #CARTCells #Innovation #CancerTreatment #Biotechnology #Astellas #KeloniaTherapeutics #HealthcareInnovation

#Adenoviruses are paving the way for revolutionary advancements in #genetherapy and #geneediting. Accounting for about 15% of gene therapy efforts, these versatile viruses deliver therapeutic genes directly into target cells, offering promising treatments for #geneticdisorders and cancers. Adenoviruses allow for sustained gene expressions and recently discovered isolates offer unique advantages like reduced antibody resistance and enhanced targeting capabilities, opening doors for novel therapeutic applications. #Clinicaltrials have shown potential applications of adenovirus-based treatments for #cysticfibrosis, #hemophilia, and even #cancer. As research progresses, the combination of adenoviruses with #CRISPR technology holds transformative potential for the future of gene editing and therapy.

The latest quarterly Gene, Cell & RNA Therapy Landscape Report by Citeline and the association with the American Society of Gene & Cell Therapy highlights significant growth in cell and gene therapies. https://lnkd.in/gX5Pr4x9 With over 4,000 therapies in development, including a notable increase in Phase I, II, and III programs, the potential to address unmet medical needs is expanding rapidly. Oncology remains a key focus, but there's also seeing a rise in non-oncology applications. Click the link in this post to read the full article. #Pipeline2Patient #FollowNorstella

The latest quarterly Gene, Cell & RNA Therapy Landscape Report by Citeline and the association with the American Society of Gene & Cell Therapy highlights significant growth in cell and gene therapies. https://lnkd.in/gr4fEZmD With over 4,000 therapies in development, including a notable increase in Phase I, II, and III programs, the potential to address unmet medical needs is expanding rapidly. Oncology remains a key focus, but there's also seeing a rise in non-oncology applications. Click the link in this post to read the full article. #Pipeline2Patient #FollowNorstella

#GeneTherapy Industry is projected to witness a CAGR of 19.4% during the period 2023-2032. This growth can be attributed to the growing prevalence of cancer, genetic, and #rarediseases.

Changing Perspectives: 20 Years Later, Cancer Due to Gene Therapy is Acceptable Twenty years ago, the FDA halted all gene therapy clinical trials based on reports from France of cancers in children who received gene therapy. When last week, it was reported that deadly cancers emerged within 2 years in seven out of 67 children who received an FDA-approved gene therapy, the Agency took a wait and see approach. Read More: https://lnkd.in/g5nxbuMq Author: Dr. Mukesh Kumar, PhD, RAC, | CEO, FDAMAP #fda #cancer #genetherapy #clinicaltrials #clinicalstudy #clinicalresearch #clinicaldevelopment #fdaregulations #fdacompliance

Vironexis Biotherapeutics' technology was created to answer one question: What's a better way to give bispecifics instead of weeks-long infusions? But the solution the team has come up with -- an off-the-shelf gene therapy that essentially turns a patient's liver into a long-lasting, bispecific-producing factory -- could turn oncology care on its head. Not only could this method work against blood cancers, but the team envisions giving a gene therapy dose to patients with solid tumors to prevent metastasis. "We realized over time that it's not just about giving a BiTE in a better way. It's more about creating a system where a single-dose infusion endows the T-cells with recognition for a target," Timothy Cripe, the brains behind Vironexis' TransJoin platform, told me. The company, which emerged from stealth today with $26 million in seed funding, was also co-founded by AveXis veteran Brian Kaspar and is helmed by Samit Varma as CEO. For more on Vironexis' tech and pipeline, which is already bursting with 10 gene therapies, read here: https://lnkd.in/gQiaDXGX

The latest quarterly Gene, Cell & RNA Therapy Landscape Report by Citeline and the association with the American Society of Gene & Cell Therapy highlights significant growth in cell and gene therapies. https://lnkd.in/gqBeJeNK With over 4,000 therapies in development, including a notable increase in Phase I, II, and III programs, the potential to address unmet medical needs is expanding rapidly. Oncology remains a key focus, but there's also seeing a rise in non-oncology applications. Click the link in this post to read the full article. #Pipeline2Patient #FollowNorstella